Acrivon Therapeutics appoints Mansoor Raza Mirza as CMO effective April 9, 2025

Acrivon Therapeutics, Inc.

Dr. Mirza is a gynecologic oncology KOL who led registrational trials for Zejula (PARP inhibitor) and frontline endometrial cancer therapy.
Current CMO Jean-Marie Cuillerot departs on April 9, 2025.
Dr. Mirza will lead Phase 2b trial of ACR-368 for endometrial cancer and Phase 1 trial of ACR-2316.
He previously served as chief oncologist at Copenhagen University Hospital and medical director of NSGO CTU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.